Beyond chemotherapy, the treatment landscape of metastatic/unresectable anal cancer has broadened with the advent of anti-programmed death-(ligand) 1 [anti-PD-(L)1] antibodies, with responses reported in 11–24% of cases with treatment-refractory incurable anal cancer [17,18,19,20,21]. Here, CD274 is linked to anal carcinoma.